<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT</h1>
  <ul>
<li>For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million net loss in Q2 2024.</li>
<li>R&amp;D expenses were $34.7 million, compared to $14.9 million a year earlier, and G&amp;A expenses were $10.5 million, up from $7.8 million in Q2 2024.</li>
<li>On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target.</li>
<li>The company also announced that it received a $10 million milestone payment from Merck after the first patient was dosed in a lead collaboration program.</li>
<li>(NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.</li>
<li>READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.</li>
<li>Both JANX007 and JANX008 are currently enrolling patients in their respective Phase 1 clinical trials.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/truist-initiates-coverage-janux-therapeutics-130926769.html">Source</a> · 2025-09-15T13:09:26+00:00</p>
</body>
</html>